AdminiStration of Statin On Acute Ischemic stRoke patienT Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

270 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators will study whether immediate statin treatment after the onset of stroke is beneficial on the neurological protection

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke

NCT02452502

Stroke

COMPLETED NA

Argatroban Combined With Antiplatelet Versus Antiplatelet for Acute Ischemic Stroke

NCT03552354

Stroke, Ischemic

COMPLETED PHASE4

Standard Medical Management in Secondary Prevention of Ischemic Stroke in China

NCT00664846

Stroke

COMPLETED NA

Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

NCT00821821

Acute Ischemic Stroke (AIS)

COMPLETED PHASE2

EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs

NCT05429476

Stroke, Acute Ischemic

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is much more important in Japan than Western to improve the prognosis after stroke because the prevalence and mortality rate of stroke in Japan is about 3-4 times as those of acute myocardial infarction. Investigators will study whether immediate statin treatment after the onset of stroke is beneficial on the neurological protection since most of previous studies with statins just showed the preventive effects from onset of primary or recurrent cerebral infarction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acute Group

Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment initiated within 24 hours after admission

Group Type ACTIVE_COMPARATOR

Statin

Intervention Type DRUG

Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke

Stable Group

Not start or withdraw Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment for a weak after admission.

Group Type OTHER

Statin

Intervention Type DRUG

Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Statin

Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Atorvastatin, Pitavastain, Rosuvastatin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* the Informed consent will be acquired by the document.
* Age: 20 years of age or older.
* Gender: unquestioned
* hospitalization, outpatient: hospital
* Patients by MRI at the time of hospital transport, it has been confirmed diagnosed with cerebral infarction
* ingestible in within 24 hours after admission In the study treatment period, patients that can be defined treatment in this clinical study implementation plan

Exclusion Criteria

* patients with a history of hypersensitivity to the treatment agent of the present study
* Patients acute hepatitis, chronic hepatitis acute exacerbation, liver cirrhosis, it is believed that the liver cancer, liver function jaundice or the like is reduced, or a biliary obstruction
* Patients suspected of being pregnant or pregnant
* Patients in the administration of the cyclosporine or telaprevir
* patients with moderate or severe renal impairment (SCr ≧ 2.5mg / dL or eGFR \<30mg / dL)
* Patients who received a diagnosis of acute coronary syndrome within 6 months
* valvular disease, atrial fibrillation, patients with atrial thrombus
* Patients familial hypercholesterolemia
* patient admission NIHSS score is greater than or equal to 3 is more than 20 or before the onset mRS score
* patients with other doctors deemed inappropriate

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No